{"type":"trials","record":{"id":42046,"source_id":"clinicaltrials-gov","external_id":"NCT06231121","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","brief_summary":"The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Rigshospitalet, Denmark","enrollment":13,"countries":["Denmark"],"start_date":"2023-12-01","completion_date":"2024-01-19","last_update_date":"2024-01-30","source_url":"https://clinicaltrials.gov/study/NCT06231121","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Rigshospitalet, Denmark","interventions":["Faricimab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of patients responding to the treatment switch — 4 weeks","Differences in patient characteristics between individuals responding and not responding to faricimab — 4 weeks","Changes in central retinal thickness after the treatment switch — 4 weeks","Changes in pigment epithelium detachment (PED) height after the treatment switch — 4 weeks","Changes in best-corrected visual acuity after the treatment switch — 4 weeks"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Faricimab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06231121","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-12-01 to 2024-01-19","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.911Z","intervention":["Faricimab"],"participants":13,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of patients responding to the treatment switch — 4 weeks","Differences in patient characteristics between individuals responding and not responding to faricimab — 4 weeks","Changes in central retinal thickness after the treatment switch — 4 weeks","Changes in pigment epithelium detachment (PED) height after the treatment switch — 4 weeks","Changes in best-corrected visual acuity after the treatment switch — 4 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42046","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}